Paul Timpson

Paul Timpson

Auto-generated profile, based on publicly available information

Paul Timpson

Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2019 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
GFGautier Follain
Gautier Follain
DHDavid Herrmann
David Herrmann
SHSébastien Harlepp
Sébastien Harlepp
VHVincent Hyenne
Vincent Hyenne
NONaël Osmani
Naël Osmani
JGJacky G. Goetz
Jacky G. Goetz

1 November 2019 in Trends in Cancer
Verified
Journal Article
Open access
BPBrooke Pereira
Brooke Pereira
CVClaire Vennin
Claire Vennin
MPMichael Papanicolaou
Michael Papanicolaou
CCCecilia R. Chambers
Cecilia R. Chambers
DHDavid Herrmann
David Herrmann
PTPaul Timpson
Paul Timpson
Cancer-associated fibroblasts (CAFs) are one of the most significant components in the tumour microenvironment (TME), where they can perform several protumourigenic functions. Several studies have recently reported that CAFs are more heterogenous and plastic than was previously thought. As such, there has been a shift in the field to study CAF subpopulations and the emergent functions of these subsets in tumourigenesis. In this review, we explore how different aspects of CAF heterogeneity are defined and how these manifest in multiple cancers, with a focus on pancreatic ductal adenocarcinoma (PDAC). We also discuss therapeutic approaches to selectively target protumourigenic CAF functions, while avoiding normal fibroblasts, providing insight into the future of stromal targeting for the treatment of PDAC and other solid tumours.

5 April 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
CVClaire Vennin
Claire Vennin
VCVenessa T. Chin
Venessa T. Chin
SWSean Warren
Sean Warren
MLMorghan C. Lucas
Morghan C. Lucas
DHDavid Herrmann
David Herrmann
PTPaul Timpson
Paul Timpson
Fine-tuned manipulation of tumor tension and vasculature enhances response to chemotherapy and impairs metastatic spread in pancreatic cancer.

12 August 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
CVClaire Vennin
Claire Vennin
PMPauline Mélénec
Pauline Mélénec
RRRomain Rouet
Romain Rouet
Max NobisMax Nobis
Max Nobis
ACAurélie S. Cazet
Aurélie S. Cazet
PTPaul Timpson
Paul Timpson
Heterogeneous subtypes of cancer-associated fibroblasts (CAFs) coexist within pancreatic cancer tissues and can both promote and restrain disease progression. Here, we interrogate how cancer cells harboring distinct alterations in p53 manipulate CAFs. We reveal the existence of a p53-driven hierarchy, where cancer cells with a gain-of-function (GOF) mutant p53 educate a dominant population of CAFs that establish a pro-metastatic environment for GOF and null p53 cancer cells alike. We also demonstrate that CAFs educated by null p53 cancer cells may be reprogrammed by either GOF mutant p53 cells or their CAFs. We identify perlecan as a key component of this pro-metastatic environment. Using intravital imaging, we observe that these dominant CAFs delay cancer cell response to chemotherapy. Lastly, we reveal that depleting perlecan in the stroma combined with chemotherapy prolongs mouse survival, supporting it as a potential target for anti-stromal therapies in pancreatic cancer.

6 August 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MPMichael Papanicolaou
Michael Papanicolaou
APAmelia L. Parker
Amelia L. Parker
MYMichelle Yam
Michelle Yam
EFElysse C. Filipe
Elysse C. Filipe
SWSunny Z. Wu
Sunny Z. Wu
TCThomas R. Cox
Thomas R. Cox
The tumour stroma, and in particular the extracellular matrix (ECM), is a salient feature of solid tumours that plays a crucial role in shaping their progression. Many desmoplastic tumours including breast cancer involve the significant accumulation of type I collagen. However, recently it has become clear that the precise distribution and organisation of matrix molecules such as collagen I is equally as important in the tumour as their abundance. Cancer-associated fibroblasts (CAFs) coexist within breast cancer tissues and play both pro- and anti-tumourigenic roles through remodelling the ECM. Here, using temporal proteomic profiling of decellularized tumours, we interrogate the evolving matrisome during breast cancer progression. We identify 4 key matrisomal clusters, and pinpoint collagen type XII as a critical component that regulates collagen type I organisation. Through combining our proteomics with single-cell transcriptomics, and genetic manipulation models, we show how CAF-secreted collagen XII alters collagen I organisation to create a pro-invasive microenvironment supporting metastatic dissemination. Finally, we show in patient cohorts that collagen XII may represent an indicator of breast cancer patients at high risk of metastatic relapse.

1 March 2018 in Gastroenterology
Verified
Journal Article
Closed access
CVClaire Vennin
Claire Vennin
KMKendelle J. Murphy
Kendelle J. Murphy
JMJennifer P Morton
Jennifer P Morton
TCThomas R. Cox
Thomas R. Cox
MPMarina Pajic
Marina Pajic
PTPaul Timpson
Paul Timpson